Paclitaxel poliglumex: Antimitotic drug oncolytic

Drugs of the Future

Volumn 32, Issue 9, 2007, Pages 776-780

  Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHC 12103; CISPLATIN; DOCETAXEL; ESTROGEN; GEMCITABINE; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; STOMACH CARCINOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 36348934579     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.09.1125219     Document Type: Article

References (19)

1. Li, C., Yu, D.F., Newman, R.A. et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998, 58(11): 2404-9.
2. Li, C., Newman, R.A., Wu, Q.-P. et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 2000, 46(5): 416-22.
3. Li, C., Price, J.E., Milas, L. et al. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 1999, 5(4): 891-7.
4. Auzenne, E., Donato, N.J., Li, C., Leroux, E., Price, R.E., Farquhar, D., Klostergaard, J. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with Taxol in xenogeneic compartmental models of ovarian carcinoma. Clin Cancer Res 2002, 8(2): 573-81.
5. Ke, S., Milas, L., Charnsangavej, C., Wallace, S., Li, C. Potentiation of radioresponse by polymer-drug conjugates. J Control Release 2001, 74(1-3): 237-42.
6. Boddy, A.V., Plummer, E.R., Todd, R. et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005, 11(21): 7834-40.
7. Boddy, A.V., Griffin, M.J., Sludden, J. et al. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. Cancer Chemother Pharmacol 2001, 48(1): 15-21.
8. Shaffer, S.A., Baker-Lee, C., Kennedy, J., Lai, M.S., de Vries, P., Buhler, K., Singer, J.W. In vitro and in vivo metabolism of paclitaxel poliglumex: Identification of metabolites and active proteases. Cancer Chemother Pharmacol 2007, 59(4): 537-48.
9. Veronese, M.L., Flaherty, K., Kramer, A., Konkle, B.A., Morgan, M., Stevenson, J.P., O'Dwyer, P.J. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005, 55(5): 497-501.
10. Sabbatini, P., Aghajanian, C., Dizon, D. et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 2004, 22(22): 4523-31.
11. Postma, T.J., Vermorken, J.B., Liefting, A.J., Pinedo, H.M., Heimans, J.J. Paclitaxel-induced neuropathy. Ann Oncol 1995, 6(5): 489-94.
12. Nemunaitis, J., Cunningham, C., Senzer, N. et al. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest 2005, 23(8): 671-6.
13. Langer, C., O'Byrne, K., Ross, H. et al. Xyotax™/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC): The STELLAR phase III study. Lung Cancer [11th World Conf Lung Cancer (July 3-6, Barcelona) 2005] 2005, 49(Suppl. 2): Abst O-101.
14. O'Brien, M., Bonomi, P., Langer, C. et al. Analysis of prognostic factors in chemo-naive patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 7113.
15. O'Byrne, K., Singer, J.W., Oldham, F.B., Ross, H. Effect of estrogen on outcome in two randomized phase III studies of paclitaxel poliglumex (PPX) in advanced non-small cell lung cancer (NSCLC). Eur J Cancer - Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 645.
16. Di Giovine, S., De Feudis, P., Torriani, D. et al. Effect of estrogen on cathepsin B activity and antitumor efficacy of paclitaxel poliglumex in human tumor xenografts. Eur J Cancer - Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 633.
17. Cell Therapeutics, Inc. (CTI) closes PGT306 (PIONEER) lung cancer clinical trial; new PGT306 protocol to be submitted to FDA by year end. Cell Therapeutics, Inc. News Release, December 7, 2006.
18. Cell Therapeutics, Inc. (CTI) announces XYOTAX™ has fast track designation for women with advanced lung cancer who are performance status 2 (PS2). PGT306 trial will focus on female PS2 lung cancer patients with normal estrogen levels. Cell Therapeutics, Inc. News Release, April 11, 2007.
19. Amato, R.J., Sharef, S., Khan, M. Phase II study of paclitaxel poliglumex (PPX) for androgen independent prostate cancer (AIPC). Prostate Cancer Symp (Feb 24-26, San Francisco) 2006, Abst 263.